Business
TNI BioTech, Inc. Acquires Exclusive License to the Portfolio of Patents of Dr. Bernard Bihari
TNI BioTech, Inc. Acquires Exclusive License to the Portfolio of Patents of Dr. Bernard Bihari.
About this update from Biostax Corp.
[{"type":"text","content":" 0 0 1 1105 6303 Brinen & Associates, LLC 52 14 7394 14.0 Normal 0 false false false EN-US JA X-NONE TNI BioTech, Inc. Acquires Exclusive License to the Portfolioof Patents of Dr. Bernard BihariNew York, New York - (August 28, 2012) - TNI BioTech, Inc. (PINKSHEETS: TNIB) announced that it acquired exclusive licensing rights to all of the proprietary technical information, know-how, procedures, IND, protocols, methods, prototypes, designs, data and reports, which are not readily available to others through public means, and which are owned, generated or developed through experiments or testing by Dr. Bernard Bihari. TNI BioTech, Inc., acquired the portfolio for 500,000 shares of the company’s restricted common stock and other consideration. As part of the agreement, the company agreed to maintain the patents and, in cases where additional patents have not been maintained in the last two years, TNI BioTech, Inc., plans to petition the United States Patent and Trademark Office to revive them immediately. The acquired portfolio contains six patents and applications related to: Cancer of the prostate, lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma; Infectious diseases such as 
chronic herpes virus infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, and chronic inflammatory conditions including chronic fatigue syndrome; and A treatment method for humans infected with the HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and patients suffering from AIDS-related complex (ARC). The portfolio includes all reissues or modification, reexaminations, or other related U.S. patent filings directed to the same subject matter. Licensed Patents refer to U.S. Patent No. U.S. Patent Number 6,586,443, U.S. Patent Number 6,384,044, U.S. Patent Number 6,288,074, U.S.Patent Number 5,356,900, U.S. Patent Number 5,013,739, U.S. Patent Number 4,888,346.Bernard Bihari, MD, was the discoverer of the clinical effects of Low Dose Naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr. Bihari discovered the significant effecti...